Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization

Renqiang Liu, Jinliang Wang, Yu Shao, Xijun Wang, Huilei Zhang, Lei Shuai, Jinying Ge, Zhiyuan Wen*, Zhigao Bu**

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, Heilongjiang Province, PR China

ABSTRACT

Middle East respiratory syndrome coronavirus (MERS-CoV) has been a highly threatening zoonotic pathogen since its outbreak in 2012. Similar to SARS-CoV, MERS-CoV belongs to the coronavirus family and can induce severe respiratory symptoms in humans, with an average case fatality rate of 35% according to the World Health Organization. Spike (S) protein of MERS-CoV is immunogenic and can induce neutralizing antibodies, thus is a potential major target for vaccine development. Here we constructed a chimeric virus based on the vesicular stomatitis virus (VSV) in which the G gene was replaced by MERS-CoV S gene (VSVΔG-MERS). The S protein efficiently incorporated into the viral envelope and mediated cell entry through binding its receptor, human DPP4. Knockdown of clathrin expression by siRNA drastically abrogated the infection of VSVΔG-MERS in Vero cells. Furthermore, in animal studies, the recombinant virus induced neutralizing antibodies and T cell responses in rhesus monkeys after a single intramuscular or intranasal immunization dose. Our findings indicate the potential of the chimeric VSVΔG-MERS as a rapid response vaccine candidate against emerging MERS-CoV disease.

1. Introduction

Middle East respiratory syndrome (MERS) is a severe emerging zoonotic disease. Since its initial identification in June 2012 in Saudi Arabia, MERS has caused 2090 infections and 730 deaths (case fatality rate: ~35%) in 27 countries as of November 2017 (WHO, 2017). MERS is caused by the MERS coronavirus (MERS-CoV), and belongs to the family of Coronaviridae, the genus β-coronavirus. Like SARS-CoV that belongs in the same genus, MERS-CoV is a zoonotic disease that originates from bats, suggesting that bats are the most likely natural reservoir of MERS-CoV (Annan et al., 2013; Memish et al., 2013; Wang et al., 2014; Yang et al., 2014). Studies have confirmed the presence of MERS-CoV in dromedaries in the Arabian Peninsula and North Africa (Hemida et al., 2017; Kayali and Peiris, 2015; Reusken et al., 2013). Dromedaries are thought to be the main reservoir of MERS-CoV. Although transmission of MERS-CoV from camels to humans has not been reported to date, it has been postulated that primary human infection could result from close contact with camels, which shed the virus (Azhar et al., 2014). Of note, a major MERS outbreak in South Korea resulted in 186 cases, including 36 deaths in 2015. The majority of these cases were health care workers who were in close contact with infected patients (Korea Ministry of Health and Welfare, 2015). Thus developing a MERS vaccine that can provide rapid immune response for high-risk populations (such as health care workers) is of significant importance to public health.

The coronavirus Spike protein (S) is immunogenic and is capable of inducing protective immunity against coronavirus infections including MERS-CoV and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (Yang et al., 2004; Ying et al., 2014). Indeed, MVA-based and DNA-based MERS-CoV vaccines designed with S protein as the target immunogen have proven effective in animal models (Haagmans et al., 2016; Muthumani et al., 2015; Song et al., 2013; Volz et al., 2015; Wang et al., 2015). However, these vaccine strategies require multiple dosing to elicit desired immune responses, thus may not be ideal for emergency vaccinations when facing the emerging infectious disease pandemics.

Studies have demonstrated that single-dose recombinant vesicular stomatitis virus (VSV)-based Ebola, Marburg and Lassa fever vaccines

* Corresponding author. 678 Haping Road, Xiangfang District, Harbin, Heilongjiang 150069, PR China.

** Corresponding author. 678 Haping Road, Xiangfang District, Harbin, Heilongjiang 150069, PR China.

E-mail addresses: wenzhiyuan@caas.cn (Z. Wen), buzhihao@caas.cn (Z. Bu).
can induce rapid immune protection in animal models (Geisbert et al., 2009; Marzi et al., 2015a, 2015b); for example, a large scale clinical trial of VSV-vectorized Ebola vaccine (rVSV-ZEBOV) conducted in west Africa in 2015 demonstrated that a single dose rVSV-ZEBOV immunization was highly safe and effective for humans (Henao-Restrepo et al., 2015). Here, we report a VSV-based chimeric recombinant virus, VSVΔG-MERS, in which VSV glycoprotein (G) gene was replaced by the MERS-CoV S gene. Single-dose immunization, either by the intramuscular or intranasal route, induced high-level and lasting MERS-CoV-specific neutralizing antibodies and T-cell responses in rhesus monkeys. Our results demonstrate, therefore, the potential of VSVΔG-MERS as a candidate vaccine against MERS-CoV.

2. Materials and methods

2.1. Recombinant virus construction and rescue

A previously described VSVΔG-eGFP pseudovirus system (Wang et al., 2006) was adapted and modified to construct VSVΔG-MERS and VSVΔG-eGFP-MERS. Chemically synthesized MERS-CoV S (GenBank accession No. KF186567.1) was amplified by PCR and flanked by Nhel restriction site. VSV gene-start and gene-end sequences were introduced. The PCR product was sequenced and cloned into the ΔG site of VSVΔG-eGFP plasmid (psVSVΔG-eGFP, plasmid containing VSV genomic cDNA without G gene). The resultant plasmid was named psVSVΔG-eGFP-MERS. Two Mnl sites flanking the eGFP gene so construction of the psVSVΔG-MERS plasmid was achieved by Mnl digestion and self-ligation. psVSVΔG-eGFP-MERS or psVSVΔG-MERS was co-transfected with a eukaryotic plasmid expressing VSV N, P and L protein, respectively, in BSR-T7/5 cells to rescue the recombinant virus. At 96 h post-transfection, the supernatant was harvested and clarified by low speed centrifugation, and serially passaged on Vero E6 cells for at least 3 passages until obvious green fluorescence and cytopathic effect (CPE) was observed. The rescued viruses were named VSVΔG-eGFP-MERS and VSVΔG-MERS respectively. The growth kinetics of the recombinant viruses was determined. VSVΔG-eGFP-MERS and VSVΔG-MERS were, respectively, inoculated at an MOI = 0.01 onto Vero E6 cells growing in 6-well plate and the supernatant was removed at 12 h intervals from 12 h to 96 h. The samples of each time-point were titrated on Vero E6 cells using indirect immunofluorescence by staining with mouse anti-S serum and TRITC-labeled goat anti-mouse IgG as primary and secondary antibodies. The titer was expressed as the reciprocal of the highest dilution titer (fluorescence forming unit, FFU).

2.2. Indirect immunofluorescence and Western blot assay

For Indirect immunofluorescence assay, Vero E6 cells were infected with either VSVΔG-eGFP-MERS or VSVΔG-MERS at an MOI = 1. At 24 h post-infection, cells were fixed with 3% paraformaldehyde, and cells were stained with mouse anti-S serum (pCAGGS-MERS-S immunized mouse serum) as primary antibody and TRITC-conjugated goat anti-mouse IgG as secondary antibody. Cell nuclei were stained with Hoechst 33342 (Invitrogen, Oregon, USA). Stained cells were analyzed with a Leica TCS SP5 laser scanning confocal microscope (Leica, Mannheim, Germany).

For Western blot assay, Vero E6 cells were infected with either VSVΔG-eGFP-MERS or VSVΔG-MERS at an MOI = 0.1. At 72 h post-infection, the cells were collected and lysed, the cell lysates were mixed with protein loading buffer, subjected to SDS-PAGE and subsequently electro-transferred to nitrocellulose membranes. Target band(s) were detected with mouse anti S serum and Alexa Fluor 680-conjugated donkey anti-mouse IgG (Invitrogen, Oregon, USA). The bands were visualized with an Odyssey digital fluorescence imaging system (LI-COR, Nebraska, USA).

2.3. Immunoelectron microscopy

VSVΔG-eGFP-MERS and VSVΔG-MERS were cultured and harvested from infected Vero E6 cells. Next, 1 ml supernatant was clarified by low speed centrifugation to remove cell debris, and subjected to high speed centrifugation (12,000 rpm, 10 min), after which 0.9 ml supernatant was carefully taken out and discarded. The remaining sample was gently vortexed and prepared for electron microscopy following a previously described protocol (Ge et al., 2011). Briefly, purified virus was bound to 200-mesh Formvar carbon-coated nickel grids (Electron Microscopy Sciences, Hatfield, PA). For immunolabeling, grids were blocked in PBS containing 2% globulin-free BSA (Sigma-Aldrich, St. Louis, MO) and incubated with mouse anti-S antibody. Grids were then washed in blocking buffer and incubated with 10-nm gold particle-conjugated goat anti-mouse IgG (Sigma-Aldrich, St. Louis, MO). After the final wash, the grids were negatively stained with 1% phosphotungstic acid, and subsequently examined under a model H7500 transmission electron microscope (Hitachi High Technologies, Schaumberg, IL) at 80 kV. Images were obtained by using an XR100 digital camera system (Advanced Microscopy Techniques, Danvers, MA).

2.4. Gene expression knockdown by RNA interference

To knock down the expression of the human DPP4 and clathrin gene in HEK-293 cells, we used Ambion Validated Silencer Selected siRNA (Thermo Fisher, Waltham, MA) respectively targeted to the specific sequence of DPP4 or clathrin. Briefly, siRNA (200 nM, 5 μl per well) targeting to DPP4, clathrin, VSV L gene (positive control) or irrelevant siRNA (negative control, Ambion cat no. 4390843) was pre-arrayed on 96-well cell carrier plates (Perkin Elmer, Waltham, MA). Nuclei were fixed with 3% paraformaldehyde and stained with Hoechst 33342 (Invitrogen, Oregon, USA) mixed with 60 μl of OptiMEM medium (Invitrogen, Oregon, USA) at an MOI = 0.01. At 48 h post-infection (15 h for VSV-eGFP), cells were fixed with 3% paraformaldehyde and stained with Hoechst 33342 (Invitrogen, Oregon, USA) in PBS for 1 h. Stained cells were imaged by PerkinElmer Operetta high-content system (PerkinElmer, Waltham, MA). Uninfected cells served as the reference population for background fluorescence. Fifty-two fields per well were imaged at 20 × magnification. Columbus software (PerkinElmer, Waltham, MA) was used to automatically identify and quantify green fluorescence and cell nuclei. The infection ratio was determined according to the numbers of infected versus non-infected cells. The assay was independently repeated three times.

2.5. ELISA

Enzyme-linked immunosorbent assay (ELISA) for determining S protein-specific IgG in mouse or monkey serum was performed as described previously (Kong et al., 2012). Briefly, BSR-T7/5 cells were seeded onto two wells of a 6-well plate. Cells were infected with recombinant Newcastle disease virus expressing MERS-CoV S protein (Liu et al., 2017) at an MOI = 0.1. At 24 h post-infection, the cell pellet was collected and lysed with vigorous pipetting, and the supernatant was used as coating antigen. Antibodies were detected using HRP-labeled goat anti-mouse (or monkey) IgG (Southern Biotech, Birmingham, AL). A standard curve was generated by coating the ELISA plate with serially diluted purified mouse or monkey IgG (Southern Biotech, Birmingham, AL) at known concentrations. A linear equation was obtained based on the standard IgG concentrations and their O.D values, thus the concentration of MERS-specific IgG was calculated according to the linear equation based on their O.D values and expressed as the amount of IgG.
per ml of serum (ng/ml).

2.6. Neutralization assay

Mouse and monkey serum neutralizing antibody levels were determined using VSVΔG-eGFP-MERS. To perform the neutralization assay, 25 μl of 2-fold serially-diluted serum (heat inactivated at 56 °C for 30 min before use) was mixed with 25 μl DMEM containing 5 × 10^2 TCID_{50} VSVΔG-eGFP-MERS and incubated at 37 °C for 1 h. After incubation, 50 μl of the pre-incubated mixture was added onto Vero E6 cells in triplicate wells of a 96-well plate. The GFP-expressing cells were counted at 36 h post-infection under a fluorescence microscope. Virus neutralization titers (VNT) were expressed as the reciprocal of the highest dilution of serum that showed at least 50% reduction in the number of fluorescent cells as compared with the negative control.

2.7. Animals and immunization protocol

For monkey immunizations, eight 2-year old male rhesus monkeys (obtained from Academy of Military Medical Sciences, Beijing, China) were randomly divided into two groups. Group 1 was intramuscularly (i.m) immunized with 2 × 10^5 FFU VSVΔG-MERS (preparation described below) in 2 ml medium via hind limb muscle injection under anesthesia. Group 2 was intranasally (i.n.) immunized with the same regimen as Group 1 via nostril instillation under anesthesia. All monkeys were housed in separate cages in a Biosafety Level-3 laboratory equipped with stable moisture and temperature. Monkeys were fed 3 times a day with specialized monkey puffed diet and various fresh fruits and adequate drinking water.

Ten 6-week female Balb/c mice (Vital River, Beijing, China) were intramuscularly immunized with 1 × 10^6 FFU VSVΔG-MERS in 0.1 ml medium via hind limb muscle injection. Ten control mice were intramuscularly injected with 0.1 ml medium. Mice were monitored daily for weight changes and signs of illness for 14 days. Mice were given the booster dose 3 weeks after the first dose. Mice blood was collected 2 weeks after the prime and boost immunizations, and mice sera were prepared for determining the MERS-specific IgG and neutralizing antibodies.

All animal usage was in strict accordance with the Guide for the Care and Use of Laboratory Animals of the Ministry of Science and Technology of the People’s Republic of China. The protocols were approved by the Animal Research Ethics Committee of Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

2.8. ELISPOT

Enzyme-linked immunospot (ELISPOT) assay was performed to evaluate the vaccine-induced T cell responses in monkeys. Ten days after immunization, monkey blood was drawn from lower extremity veins under anesthesia. Peripheral blood mononuclear cells (PBMC) were separated by monkey lymphocyte separation buffer (TBD sciences, Tianjin, China). To ensure adequate cell numbers, monkey PBMCs from the same group were pooled. A synthetic overlapping peptide pool containing the most numbers of spots were selected. The information of these peptides is listed in Table 1.

2.9. Statistical analysis

Two-way ANOVA with Bonferroni’s multiple comparison tests was used for statistical analysis. All P-values were two-tailed and considered statistically very significant when the associated probability was less than 0.01.

3. Results

3.1. Construction of VSVΔG-MERS and VSVΔG-eGFP-MERS and in vitro characterization of the viruses

VSVΔG-MERS and VSVΔG-eGFP-MERS were constructed and rescued based on the established VSV Indiana strain reverse genetics system (Wang et al., 2006) in which the VSV G gene was replaced by MERS-CoV S gene (an eGFP gene was inserted between the M and S gene of VSVΔG-MERS to construct VSVΔG-eGFP-MERS) as shown in Fig. 1A. The expression of S protein was confirmed by indirect immunofluorescence and Western blotting (Fig. 1B and C). Indirect immunofluorescence using anti-S protein antibody confirmed the surface expression of S protein in VSVΔG-MERS and VSVΔG-eGFP-MERS-infected Vero cells (Fig. 1B). eGFP expression was confirmed in VSVΔG-eGFP-MERS infected Vero cells. Both VSVΔG-MERS and VSVΔG-eGFP-MERS infected cells were not stained by VSV G monoclonal antibody. As shown in Fig. 1C, uncleaved S protein (faint bands above 170 kDa), S1/S2 cleaved S protein (~80 kDa) and S2' cleaved S protein (~65 kDa) (Millet and Whittaker, 2014) was detected in the purified VSVΔG-MERS and VSVΔG-eGFP-MERS virions indicating incorporation of S protein into the viral particles.

VSVΔG-MERS and VSVΔG-eGFP-MERS showed similar growth kinetics in Vero cells and their peak titers reached 1 × 10^7 FFU/ml at 72 h post-infection (Fig. 2). The recombinant viruses showed delayed growth kinetics and decreased titers compared with native VSV that reached 1 × 10^5 FFU/ml at 24 h post-infection. The genetic stability of VSVΔG-MERS and VSVΔG-eGFP-MERS was assessed by serially passaging the virus on Vero E6 cells for 10 passages, and the expression of S gene (plus eGFP gene for VSVΔG-eGFP-MERS) was confirmed by RT-PCR and immunofluorescence analyses (data not shown).

### Table 1

| S peptide^a | Peptide sequence | Amino acid position | SFC/million PBMC^b | T cell response to peptide |
|-------------|------------------|---------------------|---------------------|---------------------------|
| S55         | VDLYGGNMQFATLPL  | 271–285             | 1692                | i.m                       |
| S124        | VFOQCTAVGRQQRF   | 616–630             | 1922                | 1860                      |
| S154        | HPQVQDNLSSYFKKL  | 766–780             | 1726                | 1620                      |
| S174        | GGDFNLTLIEPVSIS  | 866–880             | 1616                | 1660                      |
| S221        | DKVNECGVAQIKRSG  | 1101–1115           | 2306                | 2246                      |
| S257        | DDKLIGNYYYNRRW   | 1280–1295           | 1880                | 1842                      |

^a Sequences were based on the S gene of MERS-CoV isolate Al-Hana 4,2013.
^b The numbers of IFN-γ-positive T lymphocytes in PBMC samples expressed as spot-forming cells (SFC/million PBMCs) were determined by S overlapping peptides and IFN-ELISPOT assay.
3.2. MERS-CoV S incorporates into the envelope of recombinant VSV and mediates cell infection by using the receptor DPP4

To further confirm the incorporation of S protein into the viral particles, electron and immunoelectron microscopy were performed. Results clearly showed the S protein incorporated into VSVΔG-MERS, VSVΔG-eGFP-MERS, and VSV-MERS (Fig. 3A, long arrows). VSV G protein was also shown on VSV and VSV-MERS particles with discrepant shape compared with MERS-CoV S protein (Fig. 3 upper panel, short stealth arrows). Immunoelectron microscopy showed the binding of gold-labeled secondary antibody to the anti-S antibody-bound S protein on the VSVΔG-MERS, VSVΔG-eGFP-MERS, and VSV-MERS particles (Fig. 3A, lower panel, long arrow indicating S protein). These results confirmed the incorporation of S protein into the chimeric viral particles.

Since VSVΔG-MERS and VSVΔG-eGFP-MERS had the native G protein replaced with MERS-CoV S protein to execute viral attachment and entry, the viruses should use human dipeptidyl peptidase 4 (DPP4) as their entry receptor (Raj et al., 2013). BHK-21 cells do not express human DPP4, and are non-permissive to MERS-CoV infection so we transfected BHK-21 cells with pCAGGS-DPP4 (a eukaryotic plasmid encoding human DPP4) prior to infecting the cells with VSVΔG-eGFP-MERS. As shown in Fig. 4A, BHK-21 cells were not infected by VSVΔG-eGFP-MERS, while DPP4-transfected BHK-21 cells were infected by the virus. Vero E6 cells are permissive cells for MERS-CoV, and our results demonstrated that VSVΔG-eGFP-MERS and VSVΔG-MERS could infect Vero E6 cells and form large syncytia (Figs. 1B and 4B). We then used human DPP4 siRNA to knock-down DPP4 expression in Vero E6 cells in advance of infection, and results showed infection of VSVΔG-eGFP-MERS was significantly reduced (Fig. 4B). These results confirmed the incorporation of functional S protein into the chimeric viral particles and demonstrated their use of human DPP4 as the cellular receptor for infection.
It has been well demonstrated that VSV enters cells by a clathrin-dependent endocytic pathway (Cureton et al., 2009). To determine whether replacement of VSV $G$ with the MERS-CoV $S$ altered the endocytic pathway of VSV$\Delta G$-MERS, clathrin knockdown and viral infection assays were carried out. Results showed significant reduction of VSV-eGFP and VSV$\Delta G$-eGFP-MERS infection after clathrin knockdown (Fig. 5). In fact, clathrin knock-down had a more severe influence on the infection rate of VSV-eGFP than for VSV$\Delta G$-eGFP-MERS, as indicated by the infection ratio decrease of VSV-eGFP (from $\sim$70% to $\sim$15%) versus that of VSV$\Delta G$-eGFP-MERS (from $\sim$55% to $\sim$20%) (Fig. 5 II). Taken together, our results indicated that VSV$\Delta G$-eGFP-MERS utilized more than one way to enter cells as shown by syncytia formation (Fig. 1B) and clathrin-mediated endocytosis (Fig. 5).

3.4. VSV$\Delta G$-MERS induces significant MERS S-specific IgG and neutralizing antibody in mice

We first characterized the safety and immunogenicity of VSV$\Delta G$-MERS in Balb/c mice. Mice were intramuscularly inoculated with $1 \times 10^6$ FFU VSV$\Delta G$-MERS and were monitored daily to detect body weight changes and signs of illness or death. Results showed all mice were healthy and did not exhibit untoward clinical signs. Body weight gain was similar between the experimental and the PBS control group mice for two weeks post-inoculation (Fig. 6A). We then evaluated
VSVΔG-MERS-induced humoral immune responses for S protein-specific IgG and neutralizing antibodies. Results showed high levels of specific IgG were detectable after the initial inoculation (measured day 14, 13 μg/ml), and specific IgG was significantly boosted after the second dose on day 21 (measured day 35, 20 μg/ml) (p < .05) (Fig. 6B). MERS neutralizing antibody was also detected after the first dose, and was significantly boosted after the second dose (p < .05) (Fig. 6C). Due to the fact that mice cannot be infected by VSVΔG-MERS, as they do not express human DPP4, these results demonstrated the potential of VSVΔG-MERS to serve as an inactivated MERS vaccine.

3.5. Single dose intramuscular or intranasal immunization of VSVΔG-MERS induces significant MERS-CoV specific humoral and T cell responses in rhesus monkeys

To further investigate the immunogenicity of the VSVΔG-MERS vaccine in non-human primates, rhesus monkeys were intramuscularly or intranasally immunized once with 2 × 10⁷ FFU of VSVΔG-MERS then specific humoral and T cell responses were evaluated. As shown in Fig. 7, single dose immunization induced significant MERS S protein specific IgG in monkeys vaccinated via both the intramuscular (i.m) and intranasal (i.n) route. IgG was detected 10-days post immunization and remained elevated for at least 42 days with the peak IgG level appearing on day 28. No statistical difference existed between i.m- and i.n-immunized monkeys at any time-point (Fig. 7A). Monkey MERS S protein neutralizing antibodies were induced after i.m or i.n immunization, and were detected on day 10 post immunization, reaching peak level at day 21 (Fig. 7B). The neutralizing antibody titer of i.m group was significantly higher than that of the i.n group at both time-points (Fig. 7B), indicating that the i.m route might better facilitate the production of neutralizing antibodies in the case of VSVΔG-MERS immunization in monkeys.

We further evaluated the T cell response in immunized monkeys by ELISPOT. An overlapping peptide pool consisted of 269 peptides spanning the MERS S protein was used to stimulate the PBMCs. The 15-mer peptides (with 10 amino acid overlap) were designed to preferentially stimulate CD8+ T cells. The IFN-γ secreting cells were counted and analyzed. As shown in Fig. 8, both i.m- and i.n-immunized
monkeys produced active T cell responses specific to the S protein peptide stimulation. Of the 269 peptides, we selected the most “dominant” peptide that induced the highest level of IFN-γ secretion (900 spots/well on average) and compared responses with the PMA+IONO positive control (1500 spots/well on average). We hypothesized that these peptides potentially contained monkey S protein-specific CD8+ T cell responses.

Fig. 6. Humoral responses of VSVΔG-MERS-immunized mice. 10 mice were intramuscularly immunized with 1 × 10^6 FFU VSVΔG-MERS, mice were observed and weighed daily for 14 days (A). At 21 days after the first dose, mice were given the booster dose. S protein specific IgG (B) and neutralizing antibody (C) was analyzed. (a), (b) \( p < .01 \).

Fig. 7. Humoral immune responses of rhesus monkeys to VSVΔG-MERS vaccination. Monkeys were immunized with 2 × 10^7 FFU of recombinant virus intramuscularly (i.m) or intranasally (i.n). Blood samples were collected at the indicated time-points. Serum IgG (A) and neutralizing antibody (B) were determined. The neutralizing antibody from both routes at the same time-point was compared. (a) \( p < .01 \).

Fig. 8. T cell responses of immunized rhesus monkeys to VSVΔG-MERS vaccination. PBMCs from immunized monkeys were tested for MERS-CoV S peptide-specific T cell responses by ELISPOT. An S protein overlapping peptide pool which contained 269 peptides (15-mers designed for CD8+ T cells) were used to stimulate the monkey PBMCs. Ex-vivo IFN-γ ELISPOT assay was performed to determine the active cells. Six peptides that yielded the most spots were selected for presentation. No statistical difference was observed in the peptides between the i.m and i.n groups.
cell epitopes. No statistical significance was observed between i.m. and i.n-immunized groups for these selected peptides (Fig. 8).

4. Discussion

In this study, we successfully constructed a VSV-based recombinant chimeric virus bearing MERS-CoV S protein as its new membrane glycoprotein to replace its own G protein. The chimeric virus, which is replication competent in permissive cells, utilized S protein as its sole membrane anchored glycoprotein and recognized human DPP4 as its receptor to complete attachment and cell entry. We further demonstrated that single-dose immunization, either by the intramuscular or intranasal route, induced a high-level and lasting MERS-CoV-specific neutralizing antibodies and T cell responses in rhesus monkeys.

To date, there are several types of MERS vaccines reported which mainly include live attenuated vaccine, DNA vaccine, subunit vaccine, and recombinant vectored vaccine (measles virus, MVA and adenovirus); thus far the DNA vaccine and recombinant vectored vaccines have been shown to be efficacious in experimental animals (Modjarrad et al., 2016). Of note, an MVA vectored vaccine was highly immunogenic and could significantly reduce the MERS-CoV excretion in dromedary camels (Haagmans et al., 2016). A measles virus vectored vaccine was also highly immunogenic and protective in human DPP4-transgenic mice (Malczyk et al., 2015). These results clearly demonstrate the great potential of a live-vectored vaccine. However, all of these are vaccines that require multiple dosing to generate desired immune responses, thus are not ideal in emergencies that necessitate rapid immune responses to emerging infectious diseases like MERS. By contrast, a single dose of VSVΔG-MERS immunization would suffice to induce ideal immune response.

In a previous study, we successfully generated a VSV pseudovirus bearing SARS-CoV S protein for neutralization assay and cell-entry assay (Ge et al., 2008), we further replaced the VSV G gene with the SARS-CoV S gene and successfully rescued the recombinant chimeric virus VSVΔG-SARS using a VSV reverse genetics system (unpublished work). Thus in the present study we constructed VSVΔG-MERS by deploying the same strategy. The rescued virus manifested delayed growth kinetics and decreased peak titer compared with the native virus (Fig. 2). S protein was, therefore, the sole viral membrane anchored glycoprotein instead of VSV G protein, and was critical in receptor binding and viral entry. Furthermore, the incorporation of S protein did not alter the morphology of the virus (bullet shaped virions, Fig. 3), but it did obviously alter the tropism and entry of the virus. The recombinant virus required human DPP4 as its cellular receptor (Fig. 4A and B). The S protein also influenced the entry mode of the recombinant virus, as shown in Fig. 1B, as significant syncytia formation was observed in VSVΔG-MERS and VSVΔG-eGFP-MERS-infected Vero E6 cells, but not in VSV-infected cells. This observation indicated that the virus utilized direct membrane fusion to enter cells, which was in accordance with the previous study that showed that MERS-CoV could enter the cells partially via direct membrane fusion (Qian et al., 2013). Our results further demonstrated clathrin played an important role in VSVΔG-eGFP-MERS entry, as shown in Fig. 5, where knocking down clathrin expression by siRNA in Vero E6 cells largely reduced the infection rate of VSVΔG-eGFP-MERS. This result indicated the recombinant virus could enter cells via clathrin-mediated endocytosis, which is in agreement with studies showing MERS-CoV could enter cells either by direct membrane fusion or by clathrin-mediated endocytosis (de Wit et al., 2016).

Our in vivo results demonstrated efficacious immunogenicity of VSVΔG-MERS in mice and rhesus monkeys. Theoretically, Balb/c mice cannot be infected by VSVΔG-MERS due to the lack of human DPP4, thus the recombinant virus was similar to an inactivated vaccine or virus-like particle vaccine for mice. Our results showed that VSVΔG-MERS induced a robust humoral immune response in mice after a two-dose i.m. immunization. Most importantly, our results demonstrated that a single i.m. or i.n. inoculation dose could induce effective humoral and T cell responses in rhesus monkeys. Quantitative ELISA results showed that recombinant virus induced high level of S protein specific IgG in both groups, and no statistical difference existed between i.m. and i.n groups at any time-point. However, results for the neutralizing antibodies were quite different where the i.m group demonstrated significantly higher levels of neutralizing antibodies than the i.n group at all time-points. While i.m inoculation was more effective in generating neutralizing antibodies than the i.n route, the levels of serum neutralizing antibodies following i.n inoculation were significantly higher than baseline and not trivial. We, therefore, suggest that in future application, a single dose vaccine can be given via both the i.n and i.m routes to ensure solid immunity. In the present study, we were unable to carry out a viral neutralizing assay using MERS-CoV due to the unavailability of MERS-CoV per se, thus we used VSVΔG-eGFP-MERS to mimic MERS-CoV to determine the neutralizing titers. This method was similar to that used with the S protein bearing pseudoviruses, such as lentiviral particles (Grehan et al., 2015; Jaume et al., 2011); while VSVΔG-eGFP-MERS is replication competent, it is more stable and suitable for the neutralizing antibody assay. To date, several MERS-CoV animal models have been reported, including rhesus macaques (de Wit et al., 2013; Munster et al., 2013; Yao et al., 2014), common marmosets (Falzarano et al., 2014), DPP4 transgenic mice (Agrawal et al., 2015; Pascal et al., 2015) and DPP4-expressing adenovirus transduced mice (Zhao et al., 2014). Due to the unavailability of MERS-CoV, a monkey challenge study could not be undertaken in the current study setting but will be undertaken in a future study. Considering the neutralizing antibody levels generated and the correlation between neutralizing antibody and protection, we speculate that the VSVΔG-MERS vaccine will confer protection against MERS-CoV.

Funding information

This study was support by National Key Technology R&D Program (2013BAD12B05).

Acknowledgments

We thank Bernard Moss (University of Tennessee Health Science Center) for providing the VSVΔG-eGFP pseudovirus system.

References

Agrawal, A.S., Garron, T., Tao, X., Peng, B.H., Wakamiya, M., Chan, T.S., Couch, R.B., Tseng, C.T., 2015. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89, 3659–3670.
Annan, A., Baldwin, H.J., Corman, V.M., Kloe, S.M., Owusu, M., Nkrumah, E.E., Badu, E.K., Amin, P., Agbenyega, O., Meyer, B., Oppong, S., Sarkodie, Y.A., Kalko, E.K., Lina, P.H., Godlevska, E.V., Reusken, C., Seebens, A., Glota-Rausch, F., Vallo, P., Tschapka, M., Drosten, C., Drexler, J.F., 2013. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg. Infect. Dis. 19, 456–459.
Azhari, E.I., El-Kafrawy, S.A., Farraj, S.A., Hassan, A.M., Al-Saeed, M.S., Hashem, A.M., Madani, T.A., 2014. Evidence for camel-to-human transmission of MERS coronavirus. Vet. J. 370, 2499–2505.
Cureton, D.K., Massol, R.H., Safarian, S., Khraishh, T.L., Whelan, S.P., 2009. Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog. 5, e1000394.
de Wit, E., Rasmussen, A.L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D.L., Fischer, E.R., Marrellaro, C., Okumura, A., Zhang, J., Scott, D., Benzke, A.G., Katze, M.G., Feldmann, H., Munster, V.J., 2013. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 110, 16598–16603.
de Wit, E., van Doremalen, N., Falzarano, D., Munster, V.J., 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534.
Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A.L., Okumura, A., Peng, X., Thomas, M.J., van Doremalen, N., Haddock, E., Nagy, L., LaCasse, R., Liu, T., Zhu, J., McClellan, J.S., Scott, D.P., Katoz, M.G., Feldmann, H., Munster, V.J., 2014. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 10, e1004250.
Ge, J., Wang, Y., Tao, L., Wen, Z., Peng, N., Yang, S., Xia, X., Yang, C., Chen, H., Bu, Z., 2011. Newcastle disease virus vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 85, 8241–8252.
